A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D

Maggie Li; Bijou Hunt; Bindu Balani; Chinwe Ogedegbe; Peter Gordon; Joshua Hayden; Nancy Glick; Anita Chang; Su Wang; Mitchell Caponi; Lisa Yarber-Cambron; Sandeep Bhat; Tyshea Ward; Madhu Suryadevara

doi:10.1111/jvh.14043

A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D

Maggie Li, Bijou Hunt, Bindu Balani, Chinwe Ogedegbe, Peter Gordon, Joshua Hayden, Nancy Glick, Anita Chang, Su Wang, Mitchell Caponi, Lisa Yarber-Cambron, Sandeep Bhat, Tyshea Ward, Madhu Suryadevara

Center for Discovery and Innovation

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Hepatitis D (HDV) is a severe infection with well-recognised clinical ramifications that remains relatively neglected and underdiagnosed; consequently, the epidemiology of HDV is poorly characterised, both in the United States and globally. In 2022, a pilot project involving eight healthcare institutions was undertaken to ascertain the prevalence of HDV in healthcare institutions with an HBV seropositivity of at least 1%, describe the characteristics of patients testing positive for HDV, and evaluate diagnostic and laboratory processes of HDV screening. From August 2022 to April 2024, a total of 106,693 patients were tested for HBsAg, of whom 65,341 (61.2%) were female and 40,863 (38.3%) were male, with a mean age of 47 years. The overall HBsAg positivity rate was 1.04% (n = 1112). Among the HBsAg+ samples, 645 (58.0%) underwent HDV Ab testing. The HDV Ab positivity rate was 0.81% (n = 9), with 2 cases of HDV RNA positivity (0.18%). The incomplete testing reflects several challenges associated with screening for both HBV and HDV. Further research is necessary to better understand the epidemiology and burden of HDV in the United States and considerations for implementation.

Original language	English
Article number	e14043
Journal	Journal of viral hepatitis
Volume	32
Issue number	1
DOIs	https://doi.org/10.1111/jvh.14043
State	Published - Jan 2025

ASJC Scopus subject areas

Hepatology
Infectious Diseases
Virology

Keywords

hepatitis B
hepatitis D
prevalence

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.14043

Cite this

@article{eb5fee7d501d4c74b7f9b00c9b79f213,

title = "A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D",

abstract = "Hepatitis D (HDV) is a severe infection with well-recognised clinical ramifications that remains relatively neglected and underdiagnosed; consequently, the epidemiology of HDV is poorly characterised, both in the United States and globally. In 2022, a pilot project involving eight healthcare institutions was undertaken to ascertain the prevalence of HDV in healthcare institutions with an HBV seropositivity of at least 1%, describe the characteristics of patients testing positive for HDV, and evaluate diagnostic and laboratory processes of HDV screening. From August 2022 to April 2024, a total of 106,693 patients were tested for HBsAg, of whom 65,341 (61.2%) were female and 40,863 (38.3%) were male, with a mean age of 47 years. The overall HBsAg positivity rate was 1.04% (n = 1112). Among the HBsAg+ samples, 645 (58.0%) underwent HDV Ab testing. The HDV Ab positivity rate was 0.81% (n = 9), with 2 cases of HDV RNA positivity (0.18%). The incomplete testing reflects several challenges associated with screening for both HBV and HDV. Further research is necessary to better understand the epidemiology and burden of HDV in the United States and considerations for implementation.",

keywords = "hepatitis B, hepatitis D, prevalence",

author = "Maggie Li and Bijou Hunt and Bindu Balani and Chinwe Ogedegbe and Peter Gordon and Joshua Hayden and Nancy Glick and Anita Chang and Su Wang and Mitchell Caponi and Lisa Yarber-Cambron and Sandeep Bhat and Tyshea Ward and Madhu Suryadevara",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Journal of Viral Hepatitis published by John Wiley & Sons Ltd.",

year = "2025",

month = jan,

doi = "10.1111/jvh.14043",

language = "English",

volume = "32",

journal = "Journal of viral hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D

AU - Li, Maggie

AU - Hunt, Bijou

AU - Balani, Bindu

AU - Ogedegbe, Chinwe

AU - Gordon, Peter

AU - Hayden, Joshua

AU - Glick, Nancy

AU - Chang, Anita

AU - Wang, Su

AU - Caponi, Mitchell

AU - Yarber-Cambron, Lisa

AU - Bhat, Sandeep

AU - Ward, Tyshea

AU - Suryadevara, Madhu

PY - 2025/1

Y1 - 2025/1

N2 - Hepatitis D (HDV) is a severe infection with well-recognised clinical ramifications that remains relatively neglected and underdiagnosed; consequently, the epidemiology of HDV is poorly characterised, both in the United States and globally. In 2022, a pilot project involving eight healthcare institutions was undertaken to ascertain the prevalence of HDV in healthcare institutions with an HBV seropositivity of at least 1%, describe the characteristics of patients testing positive for HDV, and evaluate diagnostic and laboratory processes of HDV screening. From August 2022 to April 2024, a total of 106,693 patients were tested for HBsAg, of whom 65,341 (61.2%) were female and 40,863 (38.3%) were male, with a mean age of 47 years. The overall HBsAg positivity rate was 1.04% (n = 1112). Among the HBsAg+ samples, 645 (58.0%) underwent HDV Ab testing. The HDV Ab positivity rate was 0.81% (n = 9), with 2 cases of HDV RNA positivity (0.18%). The incomplete testing reflects several challenges associated with screening for both HBV and HDV. Further research is necessary to better understand the epidemiology and burden of HDV in the United States and considerations for implementation.

AB - Hepatitis D (HDV) is a severe infection with well-recognised clinical ramifications that remains relatively neglected and underdiagnosed; consequently, the epidemiology of HDV is poorly characterised, both in the United States and globally. In 2022, a pilot project involving eight healthcare institutions was undertaken to ascertain the prevalence of HDV in healthcare institutions with an HBV seropositivity of at least 1%, describe the characteristics of patients testing positive for HDV, and evaluate diagnostic and laboratory processes of HDV screening. From August 2022 to April 2024, a total of 106,693 patients were tested for HBsAg, of whom 65,341 (61.2%) were female and 40,863 (38.3%) were male, with a mean age of 47 years. The overall HBsAg positivity rate was 1.04% (n = 1112). Among the HBsAg+ samples, 645 (58.0%) underwent HDV Ab testing. The HDV Ab positivity rate was 0.81% (n = 9), with 2 cases of HDV RNA positivity (0.18%). The incomplete testing reflects several challenges associated with screening for both HBV and HDV. Further research is necessary to better understand the epidemiology and burden of HDV in the United States and considerations for implementation.

KW - hepatitis B

KW - hepatitis D

KW - prevalence

UR - http://www.scopus.com/inward/record.url?scp=85211926852&partnerID=8YFLogxK

U2 - 10.1111/jvh.14043

DO - 10.1111/jvh.14043

M3 - Article

C2 - 39668640

SN - 1352-0504

VL - 32

JO - Journal of viral hepatitis

JF - Journal of viral hepatitis

IS - 1

M1 - e14043

ER -

A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this